FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2587523334> ?p ?o ?g. }

• W2587523334 endingPage "e673" @default.
• W2587523334 startingPage "e667" @default.
• W2587523334 abstract "The aim of this study was to evaluate the acute toxicity profiles of a moderate hypofractionated regimen with volumetric modulated arc therapy (VMAT) in patients with prostate cancer (PC) who underwent radical prostatectomy.From December 2012 to February 2016, 125 patients, previously having undergone radical prostatectomy, received adjuvant (64 patients) or salvage (61 patients) radiotherapy (RT) inside an institutional protocol of moderate hypofractionation schedule using the VMAT technique (Varian RapidArc, Palo Alto, CA). Eligible patients were < 85 years old, with an Eastern Cooperative Oncology Group performance status of 0 to 2, histologically proven adenocarcinoma of the prostate without distant metastases, and pathologic stage pT2-4 N0-1, with at least 1 of the following risk factors: capsular perforation, positive surgical margins, seminal vesicle invasion, and/or postoperative prostate-specific antigen > 0.2 ng/mL. Patients were stratified into low (1%), intermediate (9%), and high-risk (90%) groups. The median age was 68 years. The median doses were 66 Gy (range, 65.5-71.4 Gy) to the prostatic bed and 52.5 Gy (range, 50.4-54 Gy) to the pelvic lymph nodes, in 28 or 30 fractions. The acute genitourinary (GU) and gastrointestinal (GI) toxicities were scored according to the Common Terminology Criteria for Adverse Events, v4.All 125 patients completed the planned treatment, with good tolerance. After RT, the median follow-up was 18 months. Acute toxicities were recorded for the GU (G0, 45/125 [36%]; G1, 63/125 [50.4%]; G2, 16/125 [12.8%]; G3, 1/125 [0.8%]) and the GI (G0, 42/125 [33.6%]; G1, 72/125 [57.6%]; G2, 11/125 [8.8%]; no G3). Analyzing data according to RT intent, a higher rate of GU toxicity ≥ 2 was found in the adjuvant setting (17.1%) with respect to the salvage group (9.8%); P = .01 with the Fisher exact text. Furthermore, at statistical analysis, no difference was found between the type of surgery (robotic, laparoscopic, or open) and incidence of urinary incontinence (P = .8). The actuarial Kaplan-Meier rates for biochemical disease-free survival were 94% and 77% for adjuvant and salvage RT, at 36 months.Moderate hypofractionated postoperative RT with VMAT was feasible and safe with acceptable acute GU and GI toxicities. Longer follow-up is needed to assess late toxicity and clinical outcomes." @default.
• W2587523334 created "2017-02-17" @default.
• W2587523334 creator A5009864438 @default.
• W2587523334 creator A5011844809 @default.
• W2587523334 creator A5023259391 @default.
• W2587523334 creator A5025473156 @default.
• W2587523334 creator A5044173595 @default.
• W2587523334 creator A5067525027 @default.
• W2587523334 creator A5068225744 @default.
• W2587523334 creator A5068394973 @default.
• W2587523334 creator A5072822391 @default.
• W2587523334 creator A5081502557 @default.
• W2587523334 creator A5081673996 @default.
• W2587523334 creator A5091141737 @default.
• W2587523334 date "2017-08-01" @default.
• W2587523334 modified "2023-09-26" @default.
• W2587523334 title "Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity." @default.
• W2587523334 cites W1267631813 @default.
• W2587523334 cites W1486355582 @default.
• W2587523334 cites W1970324515 @default.
• W2587523334 cites W1980601718 @default.
• W2587523334 cites W1996271018 @default.
• W2587523334 cites W1997716779 @default.
• W2587523334 cites W1998990688 @default.
• W2587523334 cites W1998994702 @default.
• W2587523334 cites W2001409689 @default.
• W2587523334 cites W2040659915 @default.
• W2587523334 cites W2065120151 @default.
• W2587523334 cites W2074599661 @default.
• W2587523334 cites W2089570679 @default.
• W2587523334 cites W2099955473 @default.
• W2587523334 cites W2116691961 @default.
• W2587523334 cites W2126305071 @default.
• W2587523334 cites W2137491531 @default.
• W2587523334 cites W2140754632 @default.
• W2587523334 cites W2142967192 @default.
• W2587523334 cites W2146087749 @default.
• W2587523334 cites W2152529149 @default.
• W2587523334 cites W2160406420 @default.
• W2587523334 cites W2161565979 @default.
• W2587523334 cites W2174550223 @default.
• W2587523334 cites W2278230463 @default.
• W2587523334 cites W2407803508 @default.
• W2587523334 cites W2518794087 @default.
• W2587523334 cites W3159653447 @default.
• W2587523334 doi "https://doi.org/10.1016/j.clgc.2017.01.025" @default.
• W2587523334 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28237181" @default.
• W2587523334 hasPublicationYear "2017" @default.
• W2587523334 type Work @default.
• W2587523334 sameAs 2587523334 @default.
• W2587523334 citedByCount "35" @default.
• W2587523334 countsByYear W25875233342018 @default.
• W2587523334 countsByYear W25875233342019 @default.
• W2587523334 countsByYear W25875233342020 @default.
• W2587523334 countsByYear W25875233342021 @default.
• W2587523334 countsByYear W25875233342022 @default.
• W2587523334 countsByYear W25875233342023 @default.
• W2587523334 crossrefType "journal-article" @default.
• W2587523334 hasAuthorship W2587523334A5009864438 @default.
• W2587523334 hasAuthorship W2587523334A5011844809 @default.
• W2587523334 hasAuthorship W2587523334A5023259391 @default.
• W2587523334 hasAuthorship W2587523334A5025473156 @default.
• W2587523334 hasAuthorship W2587523334A5044173595 @default.
• W2587523334 hasAuthorship W2587523334A5067525027 @default.
• W2587523334 hasAuthorship W2587523334A5068225744 @default.
• W2587523334 hasAuthorship W2587523334A5068394973 @default.
• W2587523334 hasAuthorship W2587523334A5072822391 @default.
• W2587523334 hasAuthorship W2587523334A5081502557 @default.
• W2587523334 hasAuthorship W2587523334A5081673996 @default.
• W2587523334 hasAuthorship W2587523334A5091141737 @default.
• W2587523334 hasConcept C116263406 @default.
• W2587523334 hasConcept C121608353 @default.
• W2587523334 hasConcept C126322002 @default.
• W2587523334 hasConcept C126894567 @default.
• W2587523334 hasConcept C133507102 @default.
• W2587523334 hasConcept C141071460 @default.
• W2587523334 hasConcept C197934379 @default.
• W2587523334 hasConcept C2776235491 @default.
• W2587523334 hasConcept C2777793932 @default.
• W2587523334 hasConcept C2777899217 @default.
• W2587523334 hasConcept C2779466945 @default.
• W2587523334 hasConcept C2780192828 @default.
• W2587523334 hasConcept C2781413609 @default.
• W2587523334 hasConcept C29730261 @default.
• W2587523334 hasConcept C509974204 @default.
• W2587523334 hasConcept C71924100 @default.
• W2587523334 hasConceptScore W2587523334C116263406 @default.
• W2587523334 hasConceptScore W2587523334C121608353 @default.
• W2587523334 hasConceptScore W2587523334C126322002 @default.
• W2587523334 hasConceptScore W2587523334C126894567 @default.
• W2587523334 hasConceptScore W2587523334C133507102 @default.
• W2587523334 hasConceptScore W2587523334C141071460 @default.
• W2587523334 hasConceptScore W2587523334C197934379 @default.
• W2587523334 hasConceptScore W2587523334C2776235491 @default.
• W2587523334 hasConceptScore W2587523334C2777793932 @default.
• W2587523334 hasConceptScore W2587523334C2777899217 @default.
• W2587523334 hasConceptScore W2587523334C2779466945 @default.
• W2587523334 hasConceptScore W2587523334C2780192828 @default.

• next